Literature DB >> 8730845

Intrastriatal injection of GDNF attenuates the effects of 6-hydroxydopamine.

C W Shults1, T Kimber, D Martin.   

Abstract

Our study was designed to determine whether intrastriatal administration of glial cell line-derived neurotrophic factor (GDNF) can attenuate the behavioral effects and injury to the mesostriatal dopaminergic system caused by 6-hydroxydopamine (6-OHDA). Four groups of rats received a series of four intrastriatal injections of vehicle or one of three doses of GDNF (0.1, 1 or 10 micrograms per injection) on days 1,3,5 and 8. On day 4 the animals received a single, intrastriatal injection of 25 micrograms 6-OHDA. Treatment with GDNF significantly reduced the development of amphetamine-induced rotation, and the dose of 1 microgram per injection appeared to be the most effective. The group treated with this dose had significantly greater preservation of tyrosine hydroxylase-immunoreactive (TH-IR) fibers adjacent to the injection site in the striatum and significantly greater preservation of Nissl-stained and TH-IR neurons in the substantia nigra pars compacta (SNpc).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730845     DOI: 10.1097/00001756-199601310-00060

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  12 in total

Review 1.  Emerging therapies in the pharmacological treatment of Parkinson's disease.

Authors:  Amos D Korczyn; Miri Nussbaum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease.

Authors:  J Garcia de Yebenes; J Yebenes; M A Mena
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 3.  Gene therapy for Parkinson's disease.

Authors:  P Horellou; J Mallet
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

4.  GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine.

Authors:  W A Cass
Journal:  J Neurosci       Date:  1996-12-15       Impact factor: 6.167

5.  Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats.

Authors:  R J Mandel; S K Spratt; R O Snyder; S E Leff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

Review 6.  Neurotrophic factors for the investigation and treatment of movement disorders.

Authors:  Justo Garcia De Yébenes; Marina Sánchez; Maria Angeles Mena
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

7.  Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.

Authors:  X Yue; D J Hariri; B Caballero; S Zhang; M J Bartlett; O Kaut; D W Mount; U Wüllner; S J Sherman; T Falk
Journal:  Neuroscience       Date:  2013-11-27       Impact factor: 3.590

8.  GDNF protection against 6-OHDA-induced reductions in potassium-evoked overflow of striatal dopamine.

Authors:  W A Cass; M W Manning
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

Review 9.  Therapeutic potential of nerve growth factors in Parkinson's disease.

Authors:  T J Collier; C E Sortwell
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

10.  The structure of the glial cell line-derived neurotrophic factor-coreceptor complex: insights into RET signaling and heparin binding.

Authors:  Vimal Parkash; Veli-Matti Leppänen; Heidi Virtanen; Jaana M Jurvansuu; Maxim M Bespalov; Yulia A Sidorova; Pia Runeberg-Roos; Mart Saarma; Adrian Goldman
Journal:  J Biol Chem       Date:  2008-10-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.